Comparable bioavailability of two esophago-gastric protective formulations containing pamidronate: A cross-over trial in healthy young adults
Medicina (B.Aires)
;
62(4): 317-322, 2002. tab, graf
Artigo
em Inglês
| LILACS
| ID: lil-317322
RESUMO
The net absorbable amount of pamidronate (APD), according to AUC values assessed in blood, in the customary dose interval of 24 hours, was found to be similar in 8 healthy young volunteers, who received single doses of 3 capsules of 100 mg APD (AUC0-24 = 510.3 +/- 91.5 micrograms/L x h-1) and 2 tablets of 150 mg (AUC0-24 = 580.5 +/- 117.6 micrograms/L x h-1; p = 0.58) in the fasting state. Both formulations present acid-resistant coatings, designed to protect the mucosa of the upper digestive system from contact with insoluble particles of the bisphosphonates. Tmax values were different, and Cmax values presented a wide inter-individual variation, so that both formulations were not strictly bioequivalent. However, these latter factors were of minor clinical importance given the kinetic features of the bisphosphonates. In conclusion, both formulations afforded comparable bioavailability; that is to say that they can provide a sufficient amount of APD within the studied dose interval, so as to cause similar clinical effects
Texto completo:
DisponíveL
Índice:
LILACS (Américas)
Assunto principal:
Fármacos Gastrointestinais
/
Substâncias Protetoras
/
Difosfonatos
/
Anti-Inflamatórios
Tipo de estudo:
Ensaio Clínico Controlado
Limite:
Adulto
/
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Medicina (B.Aires)
Assunto da revista:
Medicina
Ano de publicação:
2002
Tipo de documento:
Artigo
País de afiliação:
Argentina
Instituição/País de afiliação:
Gador/AR
/
Instituto de Investigaciones Metabólicas/AR
Similares
MEDLINE
...
LILACS
LIS